Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Heron Therapeutics (HRTX) Net Margin: 2010-2025

Historic Net Margin for Heron Therapeutics (HRTX) over the last 11 years, with Sep 2025 value amounting to -10.71%.

  • Heron Therapeutics' Net Margin rose 288.00% to -10.71% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.03%, marking a year-over-year increase of 1985.00%. This contributed to the annual value of -9.71% for FY2024, which is 7776.00% up from last year.
  • Heron Therapeutics' Net Margin amounted to -10.71% in Q3 2025, which was down 143.40% from -4.40% recorded in Q2 2025.
  • Heron Therapeutics' Net Margin's 5-year high stood at 10.23% during Q4 2024, with a 5-year trough of -269.43% in Q2 2021.
  • Its 3-year average for Net Margin is -36.04%, with a median of -13.84% in 2024.
  • Per our database at Business Quant, Heron Therapeutics' Net Margin tumbled by 5,272bps in 2021 and then skyrocketed by 19,141bps in 2022.
  • Heron Therapeutics' Net Margin (Quarterly) stood at -259.20% in 2021, then spiked by 19,141bps to -67.79% in 2022, then soared by 3,793bps to -29.85% in 2023, then soared by 4,009bps to 10.23% in 2024, then skyrocketed by 288bps to -10.71% in 2025.
  • Its Net Margin was -10.71% in Q3 2025, compared to -4.40% in Q2 2025 and 8.11% in Q1 2025.